Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status approved; investigational
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 65015-756; 49702-203; 60687-362; 53873-075; 49702-205; 69097-167; 42385-714; 52482-003; 70966-0036; 0173-0663; 65862-055; 60505-3252; 65862-026; 69097-166; 53873-073; 55773-0589; 68554-0043; 31722-001; 49702-204; 64380-710; 68554-0016; 31722-752; 31722-754; 50742-624; 60687-720; 64380-711; 68180-602; 53104-7677; 70159-001; 31722-753; 54838-566; 57237-274; 60429-354; 66993-478; 68180-603; 53104-7538; 65015-701; 67835-0017; 60505-3250; 0904-6583; 53873-074; 65862-577; 33342-001; 0173-0662; 60505-3251; 65862-259; 65862-025; 82245-0204; 33342-002; 50742-623; 60429-353
UNII 2T8Q726O95
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.006577%
Renal injury20.01.03.015; 12.01.05.0010.003036%Not Available
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Autoimmune disorder10.04.04.003--
Bone lesion15.02.04.0160.001012%Not Available
Disease recurrence08.01.03.0500.003542%Not Available
Pancreatic enzymes abnormal13.05.01.012--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Lymphocytic infiltration01.02.01.0120.001012%Not Available
Nasal disorder22.04.03.004--Not Available
Renal impairment20.01.03.0100.010119%Not Available
Lipohypertrophy23.07.01.005; 14.08.04.0090.002226%
Respiratory tract infection11.01.08.017; 22.07.07.001--Not Available
Hyperamylasaemia14.11.01.003--Not Available
Breath sounds abnormal13.15.01.008--Not Available
Joint instability15.01.08.0070.001012%Not Available
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.004554%Not Available
Viral skin infection11.05.04.004; 23.11.05.009--Not Available
Bone marrow failure01.03.03.0050.001012%
Hyperpathia17.02.07.015--Not Available
Treatment failure08.06.01.0170.058589%Not Available
Liver injury12.01.17.012; 09.01.07.0220.001012%Not Available
Low birth weight baby18.04.02.0030.001012%Not Available
Mucosal pigmentation08.01.06.006--Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages